Hyperopic Reserve as an Indicator of Myopia Prevention by Atropine (Low-concentration Atropine for Myopia Prevention Study)

The Low-concentration Atropine for Myopia Prevention (LAMP2) study has shown that 0.05% atropine eye drops can delay the onset of myopia by 47% over 2 years. 1 Yam J.C. Zhang X.J. Zhang Y. et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023; 329: 472-481 Crossref Scopus (40) Google Scholar However, not all children are at equal risk of developing myopia, and therefore a targeted approach to minimize unnecessary treatment for those who will not develop myopia is needed. To address this research gap, we evaluate factors associated with the efficacy of low-concentration atropine in delaying myopia onset to identify whom will benefit from this prophylactic intervention. It is a secondary analysis of the LAMP2 study, a randomized, placebo-controlled, double-masked trial, and was approved by the Ethics Committee of the Hong Kong Eye Hospital and adhered to the tenets of the Declaration of Helsinki.